Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cancer Personalized Profiling Clear all
Active, not recruiting Phase 2 Interventional

Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)

NCT02152254
View directory record Official record
Conditions
Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
Interventions
Targeted Therapy Based on Molecular Profiling, Standard-of-Care Therapy
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 2, 2026, 5:35 AM EDT
Completed No phase listed Observational

Registry Study for Personalized Cancer Therapy

NCT02508662
View directory record Official record
Conditions
Advanced Cancers, Solid Tumors
Interventions
Review of Screening Tests and Molecular Test Results
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Sep 2, 2026, 5:35 AM EDT
Completed No phase listed Observational Results available

Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma

NCT02060890
View directory record Official record
Conditions
Adult Glioblastoma
Interventions
specialized tumor board recommendation
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 2, 2026, 5:35 AM EDT
Recruiting Phase 2 Interventional

Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma

NCT04965454
View directory record Official record
Conditions
Hepatocellular Carcinoma Non-resectable
Interventions
Fluorine-18 fluorocholine
Combination Product
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 2, 2026, 5:35 AM EDT
Active, not recruiting Not applicable Interventional

Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins

NCT02965755
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Treatment recommendation
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 2, 2026, 5:35 AM EDT
Recruiting Not applicable Interventional

Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma

NCT05281731
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
Sonobiopsy, Research blood, Cancer Personalized Profiling, Definity®
Device · Procedure · Genetic
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 2, 2026, 5:35 AM EDT
Recruiting Phase 1 Interventional

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

NCT05857969
View directory record Official record
Conditions
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Refractory Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Hodgkin Lymphoma, Refractory Childhood Malignant Germ Cell Neoplasm, Recurrent Childhood Brain Tumor, Recurrent Childhood Brainstem Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Ependymoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Gliosarcoma, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Childhood Malignant Solid Neoplasm, Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Malignant Neoplasm, Refractory Childhood Malignant Neoplasm
Interventions
Functional Precision Medicine
Device
Lead sponsor
Florida International University
Other
Eligibility
1 Day to 21 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 2, 2026, 5:35 AM EDT
Completed No phase listed Observational

Ex Vivo Drug Sensitivity Testing and Mutation Profiling

NCT03860376
View directory record Official record
Conditions
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Refractory Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Hodgkin Lymphoma, Refractory Childhood Malignant Germ Cell Neoplasm, Recurrent Childhood Brain Tumor, Recurrent Childhood Brainstem Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Ependymoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Gliosarcoma, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions
Not listed
Lead sponsor
Florida International University
Other
Eligibility
1 Day to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Sep 2, 2026, 5:35 AM EDT
Recruiting Phase 2 Interventional

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

NCT06954805
View directory record Official record
Conditions
Lymphoma, Lymphoma, B-Cell
Interventions
Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, CAPP-seq
Drug · Device
Lead sponsor
Jennifer Amengual
Other
Eligibility
15 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 2, 2026, 5:35 AM EDT
Terminated Phase 1 Interventional

Next Generation Personalized Neuroblastoma Therapy

NCT02780128
View directory record Official record
Conditions
Neuroblastoma, Cancer
Interventions
Biopsy, Next Generation Sequencing, Tumor Scans, Bone marrow Tests, Physical Exam, Eye Exam, Labs, Pregnancy Test, Interviews, ECG, Echocardiogram, Ribociclib, Ceritinib
Procedure · Genetic · Other + 2 more
Lead sponsor
Yael P Mosse
Other
Eligibility
1 Year to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 2, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Results available

Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")

NCT01726582
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Milestone 1: Targeted chemotherapy prior to surgery, Milestone 2: Chemoradiotherapy (cXRT), Milestone 3: Targeted chemotherapy prior to surgery, Milestone 3: Chemoradiotherapy (cXRT), Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery, Milestone 4: Chemoradiotherapy (cXRT), Milestone 5: Targeted chemotherapy after surgery, Milestone 5: Chemoradiotherapy (cXRT), Milestone 6: Gemcitabine after surgery, Milestone 6: Chemoradiotherapy (cXRT), Milestone 7: Chemoradiotherapy (cXRT), Milestone 8: Targeted chemotherapy after surgery, Milestone 9: Gemcitabine after surgery, Milestone 10: No additional therapy after surgery
Drug · Radiation · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
2
States / cities
Cincinnati, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 2, 2026, 5:35 AM EDT
Completed Not applicable Interventional

IMAGE Study: Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins

NCT01939847
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Treatment suggestion
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Sep 2, 2026, 5:35 AM EDT
Recruiting No phase listed Observational

Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors

NCT02215928
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
mutation analysis, cytology specimen collection procedure, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 2, 2026, 5:35 AM EDT
Completed Phase 1 Interventional

CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy

NCT02693080
View directory record Official record
Conditions
Malignant Lung Neoplasm, Metastatic Malignant Neoplasm in the Lung, Non-Small Cell Lung Carcinoma, Stage IV Lung Cancer
Interventions
CAPP-Seq, Isovue-200, Computed Tomography Perfusion Imaging
Device · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 2, 2026, 5:35 AM EDT
Terminated Phase 2 Interventional

Phase II Study Using Genomic & Proteomic Profiling to Influence Treatments for Patients With Metastatic Breast Cancer

NCT02008994
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Genomic and Proteomic Profiling
Other
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Sep 2, 2026, 5:35 AM EDT
Recruiting No phase listed Observational

Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)

NCT06717243
View directory record Official record
Conditions
Small Cell Lung Cancer, Large Cell Neuroendocrine (NE) Tumors, Treatment Failure, Biomarkers / Blood, Biomarkers, Immunotherapy
Interventions
Carboplatin/Cisplatin -Etoposide - Atezolizumab
Drug
Lead sponsor
Oncology Center of Biochemical Education And Research
Other
Eligibility
18 Years to 85 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 2, 2026, 5:35 AM EDT